Company profile
Oppilotech Ltd
Home - Navigating Biology, Discovering Drugs
Oppilotech Ltd is a UK company with status active founded in 2014 based in London.
Latest accounts
Financial period: 1 Feb 2024 to 31 Jan 2025
Company events
Reference milestones and recent Companies House filing stream events.
Confirmation statement due
Confirmation DueNext confirmation statement due date
Accounts due
Accounts DueNext accounts due date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Accounts With Accounts Type Total Exemption Full
Accounts AnalysedAA | Transaction MzQ0MjAwNzUyMmFkaXF6a2N4 | Paper/PDF filed
Published 06 Nov 2024 07:18
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
Development of a First-in-Class Antibiotic Targeting the Biosynthesis of the Outer Envelope of Gram-Negative Bacteria
1 Oct 2023 to 31 May 2025
Effective treatment of bacterial infections is an essential component of modern medicine. To that end, antibiotics have played a central role in saving millions of lives. Antibiotic resistance - when bacteria change so that antibiotics no longer work, is growing at a dangerously high rate and poses one of the greatest public health threats of our time. Of...
Development of Key Technologies for Real-Time Diagnosis, Surveillance and Intervention of Resistant-Bacterial Infections Based on Nanopore Sequencing
1 Jun 2020 to 30 Nov 2020
no public description
Development of Key Technologies for Real-Time Diagnosis, Surveillance and Interventionof Resistant-Bacterial Infections Based on Nanopore Sequencing
1 May 2019 to 30 Sep 2022
The proposed project aims to tackle two of the major hurdles in the fight against AMR, new drugs and new diagnostics. The new diagnostics will utilise cutting edge UK technology (Oxford Nanopore sequencing) to provide test results with unprecedented depth of information within 6 hours as opposed to the current technologies which routinely take 24-48 hours...
Development of a complete pathway model for the synthesis of the gram negative cell
1 Jan 2018 to 31 Dec 2018
It is predicted that within the next 33 years, deaths attributable to antibiotic resistant bacteria will outnumber those caused by cancer. This problem is compounded by the lack of both the discovery and development of novel antimicrobial molecules. Of particular concern are the resistance levels exhibited by the Gram -ve bacterial species such as E.coli,...
Development of a Novel Wall Teichoic Acid Inhibitor as an Oral Combination Therapy for MRSA
1 Aug 2017 to 30 Apr 2018
The emergence of multi-drug resistant bacteria is now a major public health concern. Reports from the Wellcome Trust, World Health Organization and the Chief Medical Officer of the United Kingdom have highlighted the urgent need for the identification and development of new antibiotics, especially those with novel modes of action. Antibiotic resistance wi...